The REVEAL study is an international clinical trial that aims to find out if treating cholesterol with a new drug called anacetrapib will drive down the risk of heart attacks, deaths from heart disease and other vascular diseases.
The results of the REVEAL trial were announced at the European Society of Cardiology congress in Barcelona on Tuesday 29th August 2017 and were simultaneously published in the New England Journal of Medicine. You may read or download a copy of the paper from http://www.nejm.org/doi/full/10.1056/NEJMoa1706444. The results are summarised in our press release, which is available to download here.
REVEAL involves over 30,000 men and women who already have some form of circulatory disease.
Participants were recruited from over 430 hospitals and clinics in the UK, North America, China, Germany, Italy and Scandinavia.
All study participants were given atorvastatin (a commonly used "statin" drug) to ensure good control of LDL ("bad") cholesterol.
Participants also received either anacetrapib or matching placebo (dummy) tablets daily (allocated randomly).
The primary aim of the study is to see whether fewer participants given anacetrapib have heart attacks, revascularization procedures or die from coronary heart disease than do those given the placebo tablets.
All participants stopped study treatment prior to February 2017. However further follow-up, off study treatment, is continuing for several years.
The following downloads are available:
What is the purpose of the study?
The study is called the REVEAL trial. It is investigating whether the drug anacetrapib (a CETP inhibitor)
in combination with a statin can prevent vascular disease in high risk patients.
REVEAL is the largest study looking into the possible benefits of boosting good cholesterol and further lowering bad cholesterol to prevent heart attacks and strokes in people who have suffered these conditions before, and who are already taking statins. This means that REVEAL is uniquely positioned to answer questions about the contribution of good and bad cholesterol on the risk of serious cardiovascular diseases.
Who is running and who is funding the study?
The Clinical Trial Service Unit (CTSU) in the Nuffield Department of Population Health (NDPH) at the University of Oxford is coordinating this study and has overall responsibility for the administration and coordination of the study. There is a Steering Committee to oversee the trial conduct and an independent Data Monitoring Committee perform regular analyses on data collected so far to check that the study tablets aren't causing any illness.
Funding for this study is provided by Merck Sharp & Dohme Corp. to cover the administrative and coordination costs of the trial. The University of Oxford is acting as the sponsor of this study.^Back to FAQ
Where is the REVEAL trial registered?
The REVEAL Trial is registered with the following bodies:
• ISRCTN (International Standard Randomised Controlled Trial Number): 48678192
• ClinicalTrials.gov: NCT01252953
• EU Clinical Trials Register: 2010-023467-18
• UKCRN (UK Clinical Research Network): 10598